Ra Pharma is developing an investigational drug, zilucoplan, for the treatment of patients with IMNM. Zilucoplan is designed to prevent the body’s immune attack on muscle cells by blocking a component of the body's immune system called the complement pathway.

The purpose of this study is to test the safety, tolerability, and effectiveness of zilucoplan for the treatment of patients with IMNM.

This study is a placebo-controlled study with an 8-week study treatment period. Study participants can continue their standard of care treatment during the study and will receive study drug as a self-administered (at home) subcutaneous injection once daily.

Your participation in this study would last approximately 12 weeks and would include approximately 7 study visits. You will have an option to receive active zilucoplan (not placebo) in a long-term extension study after completing this clinical trial.

To participate in this study, you will need to meet the following main entry criteria:

1. ≥18 years and <75 years of age
2. Clinical diagnosis of IMNM
3. Presence of antibodies for anti-HMGCR or anti-SRP
4. Creatine Kinase > 1000

*Other inclusion or exclusion criteria may apply.

If you're interested in participating in this trial please contact: trials@rapharma.com